Abstract
Polycystic ovarian syndrome (PCOS) is an endocrine disorder commonly
affecting women of reproductive age. It is characterized by increased
androgens, metabolic dysfunction and irregular or absent menstrual periods.
The study aimed to estimate the level of adiponectin and lipid profile related
with polycystic ovarian syndrome. The study included 90 women between
September 2024 to September 2025 with a range of ages (15-45years)
(28.666±6.837), divided into two groups: 45 with a mean (31.689±6.842) used
as healthy and 45 with mean of age (24.644±5.390) as patients. The serum
adiponectin, anti-mullerian hormone (AMH), luteinizing hormone (LH),
follicular stimulation hormone (FSH), prolactin, and t.testosterone, were
quantified through Enzyme-Linked Immunosorbent Assay (ELISA)
techniques. lipid profile (Cholesterol, Triglyceride, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), and very-low density lipoprotein
(VLDL) measurement by spectrophotometer. The result found a significant
decrease (p≤0.01) in adiponectin, high density lipoprotein (HDL) and
follicular stimulation hormone (FSH) in the PCOS patient compared to the
healthy group, also in the hormonal level, a significant increase(p≤0.01) in
anti-mullerian hormone (AMH), luteinizing hormone(LH), prolactin,
testosterone, lipid profile demonstrated a statistically significant increase
(p≤0.01) in the LDL, cholesterol, TG, VLDL, adiponectin AUC:95.704%,
with Sensitivity to Specificity 93.333%-97.678%. Low adiponectin and
dyslipidemia are connected to the pathophysiology of PCOS and can be uses
as clinical marker for PCOS.